Santyl

Santyl

a trademark for an enzyme (collagenase).
Mentioned in ?
References in periodicals archive ?
Symposium: Use of Collagenase SANTYL Ointment in Wound Bed Preparation; Wednesday, April 29; 6:00 -- 7:30 PM CT; registration required
As well as continuing to market our existing products such as Santyl, we will retain our focus on the development and commercialization of novel, cost-effective biopharmaceuticals for dermal repair and regeneration.
7] Rao D B, Sane P G and Georgiev E L 1975 The Effects of Santyl and Infection on Burn Healing in Swine; J.
BioSpecifics produces Collagenase ABC, the essential ingredient in the prescription drug Collagenase Santyl sold in the United States, and under other trademarks abroad.
This represents a decrease of approximately 19% from the same period in 2013 and was mainly due to the August 2013 expiration of the right to receive earn-out payments on Santyl partially offset by increased XIAFLEX royalties and the mark-up on cost of goods sold revenue.
SANTYL, SURGICEPT, THE WOUND INSTITUTE and THEWOUNDINSTITUTE.
Santyl, Surgicept, and The Wound Institute are registered trademarks of Healthpoint, Ltd.
BioSpecifics has now recognized all income from the Santyl sales under the DFB agreement, and in March 2014, the Company received the final cash payment for the income recognized in 2013.
Santyl, Surgicept, and Wound Institute are registered trademarks of Healthpoint, Ltd.
131 Smith & Nephew's Collagenase Santyl Ointment132 Maggot Therapy133 Lohmann & Rauscher's Debrisoft.
Misonix Adds SonicOneA Technology to BoneScalpel(TM) Platform II-30 IrriMax Launches IrriSept Wound Cleansing and Debridement System II-30 Healthpoint Biotherapeutics to Unveil Collagenase SANTYL Ointment II-30 ArthroCare Introduces WoundWand Debridement Care Device II-31 Spring Creek Inks Licensing Contract with McCoy Enterprises II-31 Misonix Signs Exclusive Distribution Agreement with EuroTech(TM) II-31 5.
Under this agreement with DFB, pursuant to which BioSpecifics sold its topical collagenase business, BioSpecifics had the right to receive earn-out payments based on Santyl sales, which right expired in August 2013.